<DOC>
	<DOCNO>NCT00660621</DOCNO>
	<brief_summary>To determine safety efficacy surgical resection Gliadel® 3.85 % wafer implantation , follow concomitant limited field radiation therapy temozolomide , follow dose dense temozolomide bevacizumab subject undergoing initial surgery newly-diagnosed high grade glioma .</brief_summary>
	<brief_title>A Phase II Study Of Gliadel , Concomitant Temozolomide And Radiation , Followed By Dose Dense Therapy With Temozolomide Plus Bevacizumab For Newly Diagnosed Malignant High Grade Glioma</brief_title>
	<detailed_description />
	<mesh_term>Glioma</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<mesh_term>Temozolomide</mesh_term>
	<mesh_term>Dacarbazine</mesh_term>
	<criteria>Subjects , men woman , must age 18 75 year . Subjects must radiographic evidence cranial magnetic resonance imaging ( MRI ) single , contrastenhancing unilateral supratentorial cerebral tumor . Surgery recommend within 4 week baseline MRI scan . Subjects must Karnofsky Performance Score 60 high . Subjects must sign Institutional Review Board ( IRB ) approve informed consent prior nonstandard care study procedure later start dose dense temozolomide bevacizumab.. Subjects must pathological diagnosis high grade ( IV ) malignant glioma . Subjects , men woman , must willing avoid pregnancy 2 year wafer implantation surgery counsel regard unknown , potentially harmful , risk embryo fetus participation study . Subjects prior cytoreductive surgery highgrade glioma . Subjects diagnostic stereotactic biopsy eligible . Subjects one focus tumor tumor cross midline assess coronal cranial MRI scan . Concomitant significant lifethreatening disease subject could reasonably expect die within first 12 month study . Known hypersensitivity reaction temozolomide , nitrosoureas component Gliadel® wafer . Prior CNS radiotherapy . Subjects receive prior chemotherapy malignant glioma prior baseline evaluation subject currently treat chemotherapeutic agent . Subjects few 100,000 platelet per mm3 few 3.500 leukocyte per mm3 . Liver function test great equal 2.5 time upper limit normal ( transaminase ( SGOT , SGPT ) , total bilirubin , alkaline phosphatase ) . Serum creatinine equal great 1.5 time upper limit normal , blood urea nitrogen ( BUN ) equal great 2.5 time upper limit normal . Pregnancy , lactate female female childbearing potential use adequate contraception . Participation investigational protocol prior twelve month type malignancy . Psychological , familial , sociological geographical condition permit adequate medical followup compliance study protocol . Inadequately control hypertension ( blood pressure systolic &gt; 150 mmHg diastolic &gt; 100 mmHg ) . Unstable angina history myocardial infarction within six month prior enrollment . Evidence bleeding , diathesis , coagulopathy . Chronic fulldose anticoagulation warfarin permit though subject may low molecular weight heparin fondaparinux . Serious nonhealing wound , ulcer , bone fracture .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>January 2010</verification_date>
	<keyword>High Grade</keyword>
	<keyword>Malignant</keyword>
	<keyword>GBM</keyword>
</DOC>